Non Hodgkin Lymphoma Clinical Trial

Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma

Summary

The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK), immunogenicity and preliminary efficacy of VAY736 alone or in combination with other therapies in patients with NHL in a platform trial.

View Full Description

Full Description

The primary objective of the study is to evaluate the safety and tolerability in patients with NHL and identify a maximum tolerated dose (MTD) and/or recommended dose (RD) of VAY736 single agent and in combination with other anti-cancer therapies.

This is a phase I/Ib, multi-center, open-label study with multiple treatment arms in an adaptive study design. The study is comprised of a dose escalation part and dose expansion part.

In dose escalation, the investigational drug VAY736 will be explored alone or in combination with partner therapies. Increasing doses of VAY736 alone or in combination will be given to small groups of patients to identify the MTD/RD in patients with NHL. In dose expansion, some or all the treatments from dose escalation will be tested at the recommended doses in patients with NHL. The combination partners include lenalidomide and CC-99282. Other combination partners may be added in the future by protocol amendment. The study is expected to be approximately 4 years in duration (from enrollment of first patient to discontinuation of last patient).

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Adult patients with confirmed diagnosis of relapsed/refractory B-cell NHL with all subtypes of DLBCL, follicular lymphoma (FL), marginal zone lymphoma (MZL) and mantle cell lymphoma (MCL) per WHO 2016 criteria. Patients in subtype arm e.g. DLBCL must have confirmed diagnosis of relapsed/refractory DLBCL.
Received and failed or be intolerant to standard of care therapy (at least two prior lines, including an anti-CD20 therapy for NHL)
Must have measurable disease and ECOG of 0 to 2

Exclusion Criteria:

Baseline laboratory results outside of protocol defined ranges
Patients with primary CNS lymphoma
History of hypersensitivity to VAY736 or any drugs in similar chemical classes (e.g. monoclonal antibodies)
Impaired cardiac function or clinically significant cardiac disease
History of or current interstitial lung disease or pneumonitis grade 2 or higher
HIV infection
Active hepatitis C infection and/or hepatitis B infection
Pregnant or nursing (lactating) women
Women of child-bearing potential unless they are using highly effective methods of contraception

Other Inclusion/Exclusion criteria may apply

Study is for people with:

Non Hodgkin Lymphoma

Phase:

Phase 1

Estimated Enrollment:

124

Study ID:

NCT04903197

Recruitment Status:

Recruiting

Sponsor:

Novartis Pharmaceuticals

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 19 Locations for this study

See Locations Near You

City of Hope National Med Ctr
Duarte California, 91010, United States More Info
Swetha Kambhampati
Principal Investigator
The Ohio State University James Cancer Hospital &
Columbus Ohio, 43210, United States More Info
Shayla Thompson
Contact
614-293-2268
[email protected]
David A Bond
Principal Investigator
MD Anderson Cancer Center
Houston Texas, 77030, United States More Info
Carolyn Hawkins
Contact
713-792-0007
[email protected]
Jason Westin
Principal Investigator
Novartis Investigative Site
Melbourne Victoria, 3004, Australia
Novartis Investigative Site
Nanjing Jiangsu, 21002, China
Novartis Investigative Site
Shanghai Shanghai, 20003, China
Novartis Investigative Site
Tianjin Tianjin, 30002, China
Novartis Investigative Site
Koeln , 50937, Germany
Novartis Investigative Site
Leipzig , 04103, Germany
Novartis Investigative Site
Brescia BS, 25123, Italy
Novartis Investigative Site
Milano MI, 20133, Italy
Novartis Investigative Site
Rozzano MI, 20089, Italy
Novartis Investigative Site
Koto ku Tokyo, 135 8, Japan
Novartis Investigative Site
Yamagata , 990 9, Japan
Novartis Investigative Site
Seoul , 03080, Korea, Republic of
Novartis Investigative Site
Seoul , 05505, Korea, Republic of
Novartis Investigative Site
Singapore , 11922, Singapore
Novartis Investigative Site
Madrid , 28034, Spain
Novartis Investigative Site
Madrid , 28041, Spain

How clear is this clinincal trial information?

Study is for people with:

Non Hodgkin Lymphoma

Phase:

Phase 1

Estimated Enrollment:

124

Study ID:

NCT04903197

Recruitment Status:

Recruiting

Sponsor:


Novartis Pharmaceuticals

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.